XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenue:        
Total revenue $ 87 $ 108 $ 251 $ 484
Operating expenses:        
Cost of revenue 18 12 52 83
Research and development 4,471 5,972 14,490 19,982
General and administrative 3,413 3,666 10,147 11,029
Total operating expenses 7,902 9,650 24,689 31,094
Loss from operations (7,815) (9,542) (24,438) (30,610)
Other income (expense), net:        
Interest income 127 546 755 931
Interest expense (1,022) (1,188) (3,548) (3,358)
Commitment share expense 0 0 0 (402)
Issuance costs for common stock warrant liabilities 0 0 0 (333)
Loss on initial issuance of equity 0 0 0 (14,840)
Change in fair value of common stock warrant liabilities 697 6,341 956 5,958
Change in fair value of Clene Nanomedicine contingent earn-out liability 0 1,004 75 2,114
Change in fair value of Initial Stockholders contingent earn-out liability 0 129 10 272
Research and development tax credits and unrestricted grants 27 247 339 902
Other income, net 0 45 0 35
Total other income (expense), net (171) 7,124 (1,413) (8,721)
Net loss before income taxes (7,986) (2,418) (25,851) (39,331)
Income tax expense 0 0 0 0
Net loss (7,986) (2,418) (25,851) (39,331)
Other comprehensive income (loss):        
Unrealized gain (loss) on available-for-sale securities 1 (4) (1) 16
Foreign currency translation adjustments 52 (81) 25 (130)
Total other comprehensive income (loss) 53 (85) 24 (114)
Comprehensive loss $ (7,933) $ (2,503) $ (25,827) $ (39,445)
Net loss per share – basic and diluted (in dollars per share) $ (1.22) $ (0.38) $ (4) $ (8.11)
Weighted average common shares used to compute basic and diluted net loss per share (in shares) 6,557,839 6,420,274 6,467,771 4,851,348
Product [Member]        
Revenue:        
Total revenue $ 65 $ 65 $ 173 $ 355
Royalty [Member]        
Revenue:        
Total revenue $ 22 $ 43 $ 78 $ 129